相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

编程死亡-1抑制在前列腺癌患者中增加了疫苗诱导的T细胞透

Wiem Lassoued¹, Ravi A Madan², Elisabetta Xue¹

¹Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Journal for immunotherapy of cancer

|June 23, 2025

概括

这项研究将PROSTVAC疫苗与nivolumab结合用于治疗前列腺癌,显示免疫细胞活性增加和患者有希望的反应. 组合疗法可能会增强免疫检查点抑制剂的有效性.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
疫苗学疫苗学疫苗学

背景情况:

前列腺癌 (PC) 是全球男性的主要癌症诊断,死亡率很高.
目前的免疫检查点抑制剂 (ICI) 仅限于特定的高突变负担PC.
需要结合策略,通过诱导免疫反应来扩大ICI的效用.

研究的目的:

调查前列腺特异抗原 (PSA) 向癌症疫苗PROSTVAC的安全性和有效性.
在前列腺癌患者中评估与nivolumab (抗PD-1抑制剂) 结合使用的PROSTVAC.
评估对免疫细胞透,T细胞反应和临床结果的影响.

主要方法:

阶段1/2试验招募了两个队列:转移性割耐药PC (mCRPC) 引入 (n=12) 和局部PC新辅助剂 (n=12).
治疗包括PROSTVAC疫苗和尼沃卢马布.
评估了内免疫细胞,PD-L1表达,血清分析物和抗原特异性T细胞反应 (PSA,brachyury,MUC-1).

主要成果:

领先队列中的两名患者实现了完全的放射性反应.
新辅助者队列在91%和83%的术后样本中显示CD4+和CD8+T细胞密度增加 (>2倍).
大多数患者呈现PSA,MUC-1和brachyury特异性T细胞的增加;周围血液显示T细胞增殖增加,但T细胞总数减少.

结论:

新辅助剂PROSTVAC加尼沃卢马布增加了内T细胞和循环中的瘤抗原特异性T细胞.
这种组合疗法在mCRPC患者中显示了放射和生化反应.
疫苗添加到与瘤相关的抗原可能会增强免疫检查点抑制的临床活性.

关键词:

组合疗法是一种联合疗法.前列腺癌是前列腺癌.瘤透淋巴细胞 - - TIL

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Vaccinations

Vaccinations

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...